



February 10, 2023

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Update from Heartseed Inc.: Successful transplantation of the first case in the Phase I/II LAPiS study of HS-001, a myocardial regenerative therapy utilizing iPS cells

Tokyo, February 10, 2023 – Kidswell Bio delighted to announce that Heartseed, in which KWB has invested, released the announcement on successful transplantation of the first case in the Phase I/II LAPiS study of HS-001, a myocardial regenerative therapy utilizing iPS cells. For more detailed information, please refer to the following website of Heartseed Inc.

Heartseed Inc. official website (English)

<https://heartseed.jp/en/index.html>

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com